Zika vaccine candidate enters human safety testing
NCT ID NCT06334393
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tested an inactivated Zika virus vaccine (VLA1601) in 150 healthy adults aged 18-49. Participants received two doses, and researchers monitored side effects and immune responses. The goal was to find the safest and most effective dose, including combinations with additional immune-boosting adjuvants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VLA1601 (inactivated Zika virus vaccine with adjuvants)
What this could lead to
If successful, this could lead to a safe and effective vaccine to prevent Zika virus infection, which can cause severe birth defects.
What could go wrong
This is an early Phase 1 trial with only 150 healthy adults, so results may not apply to the general population. The vaccine may not produce a strong enough immune response or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ZIKA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Flourish Research
Chicago, Illinois, 60640, United States
-
Velocity Clinical Research
Sioux City, Iowa, 51106, United States
-
Velocity Clinical Research
Lincoln, Nebraska, 68510, United States
-
Velocity Clinical Research
Omaha, Nebraska, 68134, United States